With the HeartMate 3™ LVAD, you can
make a meaningful difference in patients' lives.

How your patients live their lives depends on the LVAD you choose. The HeartMate 3 LVAD can be used for advanced heart failure patients needing short- or long-term mechanical circulatory support (e.g., bridge to transplant (BTT) or myocardial recovery, or destination therapy (DT)).

HEARTMATE 3 LVAD DELIVERS UNPRECEDENTED* SURVIVAL AND SAFETY OUTCOMES**1

MOMENTUM 3 was the largest left ventricular assist device (LVAD) trial ever conducted.*** The results at 2 years show that the HeartMate 3™ LVAD continues to have:

79%25 24 months after implant icon
 

the highest survival rate for any lvad in a randomized controlled trial†,1-3
10%25 stroke and 1%25 thrombosis icon
 

the lowest hemocompatibility-related adverse event rates of any lvad†,††,1-4
80%25 sustained improvement in 24 months icon
 


Immediate, Significant, and Sustained Improvements in functional capacity and quality of life1

Click here to jump to the QOL data below
 
Based on published data from multicenter experience and separate studies, which may involve
different patient populations and other variables. Not a head-to-head comparison. Data presented
for informational purposes only.
See the data

outcomes made possible by Full MagLev™ Flow Technology

Full MagLev Flow Technology maintains gentle blood handling to minimize complications and reduce hemocompatibility-related adverse events.

  • Fully levitated, self-centering rotor that does not require hydrodynamic or mechanical bearings.
  • Large, consistent blood flow pathways to reduce shear stress5
  • Intrinsic pulsatility to reduce stasis and minimize thrombus5,6
HeartMate 3 MagLev Technology

HEARTMATE 3 LVAD PROVIDES IMMEDIATE, SIGNIFICANT, AND SUSTAINED IMPROVEMENTS IN FUNCTIONAL CAPACITY AND QUALITY OF LIFE1

Significant improvements in NYHA class, 6-minute walk distance, and quality of life1

Significant improvements in NYHA Class, 6-minute walk distance, and quality of life

Significant increase in 6-minute walk distance1

At baseline, tested patients completed the 6-minute walk test at an average of 136 meters. At 2 years after HeartMate 3™ LVAD implant, patients completed the test at an average of 323 meters.1

Football field graphic showing 6 minute walk distance
Review the data
DOWNLOAD THE
HeartMate 3 LVAD BROCHURE
CONTACT AN
ABBOTT REPRESENTATIVE

*Based on HeartMate 3™ LVAD highest published survival and lowest published stroke and thrombosis rates in continuous-flow LVAD category of devices in the U.S.1-4
** HeartMate 3 LVAD demonstrated superiority in event-free survival (primary endpoint) in the MOMENTUM 3 trial compared to HeartMate II™ LVAD.
***Ongoing evaluation of more than 2,000 patients on short- and long-term therapy of devices in the U.S.1,9,10,11
†For a continuous-flow LVAD in a randomized controlled trial.
††Key adverse events include pump thrombosis, stroke and gastrointestinal bleeding.

Indications and Important Safety Information

Rx Only
Brief Summary: Prior to using these devices, please review the Instructions For Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use.

Indications: The HeartMate 3 Left Ventricular Assist System is indicated for providing short- and long-term mechanical circulatory support (e.g., as bridge to transplant or myocardial recovery, or destination therapy) in adult and pediatric patients with advanced refractory left ventricular heart failure and with an appropriate body surface area.

Contraindications: The HeartMate 3™ Left Ventricular Assist System is contraindicated for patients who cannot tolerate, or who are allergic to, anticoagulationtherapy.

Adverse Events: Adverse events that may be associated with the use of the HeartMate 3™ Left Ventricular Assist System are: death, bleeding, cardiac arrhythmia, localized infection, right heart failure, respiratory failure, device malfunctions, driveline infection, renal dysfunction, sepsis, stroke, other neurological event (not stroke-related), hepatic dysfunction, psychiatric episode, venous thromboembolism, hypertension, arterial non-central nervous system (CNS) thromboembolism, pericardial fluid collection, pump pocket or pseudo pocket infection, myocardial infarction, wound dehiscence, hemolysis (not associated with suspected device thrombosis) or pump thrombosis.

References: 1. Mehra M, Uriel N, Naka Y, et al. A Fully Magnetically Levitated Ventricular Assist Device-Final Report. N Engl J Med. 2019;380:1618-1627.  2. Rogers JG, Pagani F, Tatooles A, et al. Intrapericardial left ventricular assist device for advanced heart failure. New Engl J Med. 2017;376:451-460.  3. Markham DW. Two-year Outcomes in the ENDURANCE Supplemental Trial. American Heart Association (AHA) Annual Meeting; November 10, 2018; Chicago, IL.  4. Uriel N. Long-Term Burden of Hemocompatibility Related Adverse Events in the MOMENTUM 3 Trial: Final Analysis of the 1028 Patient Cohort. The International Society for Heart & Lung Transplantation (ISHLT) Annual Meeting; April 4, 2019; Orlando, FL.  5. Bourque K, Cotter C, Dague C, et al. Design rationale and preclinical evaluation of the HeartMate 3 Left Ventricular Assist System for hemocompatibility. Am Soc Artificial Int Organs. 2016;62:375-383. 6. Bourque K, Dague C, Farrar D, et al. In vivo assessment of a rotary left ventricular assist device-induced artificial pulse in the proximal and distal aorta. Artificial Organs. 2006;30:638-642. 7. Abbott. Data on File.  8. Mehra MR. A Fully Magnetically Levitated Left Ventricular Assist Device-Final Report for the MOMENTUM 3 Trial. American College of Cardiology (ACC) Annual Meeting; March 17, 2019; New Orleans, LA. 9. Khush KK, Cherikh WS, Chambers DC, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-fifth Adult Heart Transplant Report-2018; Focus Theme: Multiorgan Transplantation. J Heart Lung Transplant. 018;37:1155-1168.  10. Slaughter MS, Rogers JG, Milano CA, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009;361:2241-2251. 11. Jorde UP, Kushwaha SS, Tatooles AJ, et al. Results of the destination therapy post-Food and Drug Administration approval study with a continuous flow left ventricular assist device: a prospective study using the INTERMACS‡ registry (Interagency Registry for Mechanically Assisted Circulatory Support). J Am Coll Cardiol. 2014;63:1751-1757.

MAT-1900450 v2.0